Fig. 2.

Genetic alterations of TRAIL, its receptors and KRAS and probability of progression to metastasis in AC and SCC. a cBioPortal analysis for genetic alterations of TRAIL (TNFSF10), its receptors (TNFRSF10A and B) and KRAS (multiple alterations, mutations, amplifications and deletions) in lung cancer. Numbers in parentheses indicate the number of samples. Status of TRAIL, its receptors and KRAS in individual samples along with their clinical stage of metastasis from a representative b AC c SCC TCGA study shown in Fig. 2a. Per cent genetic alterations of individual genes are indicated. d Kaplan-Meier plot for first progression with TRAIL gene in lung AC datasets. The probability of cancer progression has been plotted over a period of 120 months for patients with high or low TRAIL expressions. Numbers at risk indicate the number of patients at risk at corresponding time points e K-M plot in SCC